![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
MCI Onehealth Technologies Inc | TSX:DRDR | Toronto | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.55 | 0.55 | 0.60 | 0 | 01:00:00 |
A summary of MCI’s financial and operational results is set out below, and more detailed information is contained in the condensed interim consolidated financial statements and related management discussion and analysis, which are available on MCI’s SEDAR page at www.sedar.com. Financial measures described as “Adjusted” in this news release are non-IFRS financial measures and may not be comparable to other similar measures disclosed by other companies. Please see Non-IFRS Financial Measures below for more information.
Cash and Liquidity Update
For the three months ended March 31, 2023, the Company experienced operating losses of $7.4 million and negative cash flows from operations of $1.11 million, and as at the end of that period had a cash balance of approximately $1.4 million and accounts payable and other current liabilities of approximately $20.7 million. The Company will need to obtain additional financing by the end of May to fund ongoing operations in the ordinary course, and may be required to obtain additional financing in future periods.
To address its immediate liquidity constraints, the Company announced on April 27, 2023 that it is seeking approval for an additional $1.5 million debt financing facility from a related party to fund its ongoing operations and for general and administrative expenses. That facility remains subject to the approval of the Toronto Stock Exchange and has not yet closed. Even if the facility is implemented, it is likely that the Company will need to obtain additional sources of liquidity by the end of May to continue to fund its ongoing operations.
The Company’s special committee (the “Special Committee”), comprised of two of its independent directors, remains engaged in a process to evaluate and consider the Company's current financial and liquidity position, operational challenges and possible financing, reorganization or restructuring alternatives that may be available to the Company. The Company is also continually evaluating other alternatives for generating cash in the short term, including the potential sale of certain assets identified by the Company, and is continuing to responsibly reduce costs while it evaluates the potential options. The Company provided an update on these efforts, which are ongoing, in a press release on April 20, 2023.
Other than as described in this news release, the Company has not made any decisions related to strategic alternatives at this time. The Company cautions that there are no assurances that the evaluation of strategic alternatives will result in the approval or completion of any specific transaction or outcome and there is no certainty that the Company will be able to secure additional financing or sell assets to generate liquidity, or on what terms it will be able to do so, or that its revenue growth and expense reduction strategies will be successful.
First Quarter 2023 Financial and Operational Highlights
Significant financial and operational highlights for MCI during the three months ended March 31, 2023 included:
Selected Financial Information(in thousands of dollars, except percentages and per share amounts)
Quarter ended | Period over | ||||||||||
March 31 | period Change | ||||||||||
2023 | 2022 | $ | % | ||||||||
($ in thousands except percentages) | |||||||||||
Revenues | $11,534 | $13,020 | $(1,486) | (11) | |||||||
Cost of sales | 8,155 | 8,926 | (771) | (9) | |||||||
Gross profit | 3,379 | 4,094 | (715) | (17) | |||||||
Research and development | 1,851 | 1,830 | 21 | 1 | |||||||
Sales and marketing | 336 | 412 | (76) | (18) | |||||||
General and administrative | 5,487 | 6,615 | (1,128) | (17) | |||||||
7,674 | 8,857 | (1,183) | (13) | ||||||||
Net finance costs | 355 | 132 | 223 | NM | |||||||
FV changes-contingent liabilities | (7) | - | (7) | NM | |||||||
Loss on settlement of shares-contingent consideration | 677 | - | 677 | NM | |||||||
Impairment on investments | 2,303 | - | 2,303 | NM | |||||||
Share of net loss of associate | 26 | 142 | (116) | (82) | |||||||
3,354 | 274 | 3,080 | NM | ||||||||
Loss before taxes | (7,649) | (5,037) | (2,612) | (52) | |||||||
Income taxes recoveries | (201) | (814) | 613 | 75 | |||||||
Net loss | (7,448) | (4,223) | (3,225) | (76) | |||||||
Adjusted gross profit (1) | 3,537 | 4,252 | (715) | (17) | |||||||
Adjusted gross margin (1) | 30.7% | 32.7% | |||||||||
Adjusted EBITDA (2) | (2,396) | (2,421) | 25 | 1 | |||||||
Adjusted EBITDA margin (2) | (20.8%) | (18.6%) | |||||||||
Weighted average number | |||||||||||
Of Share outstanding: Basic and diluted | 51,930,326 | 50,075,202 | |||||||||
Net loss per share -Basic and diluted | $(0.15) | $(0.09) |
(1), (2) Adjusted Gross Profit, Adjusted Gross Margin, Adjusted EBITDA and Adjusted EBITDA Margin are non-IFRS measures. Please see “Non-IFRS Financial Measures” below for more information and a reconciliation of these amounts to the IFRS measures found in the Company’s condensed interim consolidated financial statements.
Selected Statement of Financial Position Data
March 31, 2023 | December 31, 2022 | |
$ in thousands | ||
Cash | 1,403 | 1,411 |
Accounts receivable | 4,535 | 5,627 |
Other assets | 1,078 | 1,493 |
Accounts payable and accrued liabilities | (8,957) | (9,227) |
Bank loan | (1,695) | (1,685) |
Related party loan | (7,169) | (5,315) |
Lease liabilities | (9,833) | (10,420) |
Other liabilities | (130) | (130) |
Non-controlling interest redeemable liability | (1,305) | (1,305) |
Liability for contingent consideration | (30) | (1,637) |
Non-IFRS Financial Measures
The terms Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Gross Profit and Adjusted Gross Margin used in this document do not have any standardized meaning under IFRS, may not be comparable to similar financial measures disclosed by other companies and should not be considered a substitute for, or superior to, IFRS financial measures. Readers are advised to review the section entitled “Non-IFRS Financial Measures” in the Company’s management discussion and analysis for the quarter ended March 31, 2023, available on MCI’s SEDAR page at www.sedar.com, for a detailed explanation of the composition of these measures and their uses.
(1) The following table reconciles Adjusted EBITDA and Adjusted EBITDA Margin to net income (loss) for the three-months ended March 31, 2023 and March 31, 2022:
Three months ended | ||||
March 31 | ||||
2023 | 2022 | |||
$ in thousands | ||||
Total Revenue | $11,534 | $13,020 | ||
Net loss | (7,448) | (4,223) | ||
Add back (deduct) | ||||
Depreciation and amortization | 1,261 | 1,221 | ||
Net finance charges | 355 | 132 | ||
Expected credit recovery | (76) | - | ||
Loss on settlement of shares-contingent consideration | 677 | - | ||
Share of loss of associate | 26 | 142 | ||
Impairment on investments | 2,303 | - | ||
FV changes-contingent liabilities | (7) | - | ||
Income taxes recoveries | (201) | (814) | ||
Share-based payment expense | 714 | 1,121 | ||
Adjusted EBITDA | $(2,396) | $(2,421) | ||
Adjusted EBITDA Margin | (20.8%) | (18.6%) |
(2) The following table reconciles Adjusted Gross Profit and Adjusted Gross Margin to revenue and cost of sales for the three-months ended March 31, 2023 and March 31, 2022:
Three months ended | Period over | ||||||||
March 31 | period Change | ||||||||
2023 | 2022 | $ | % | ||||||
($ in thousands except percentages) | |||||||||
Revenue | $11,534 | $13,020 | $(1,486) | (11%) | |||||
Cost of sales | 8,155 | 8,926 | (771) | (9%) | |||||
Less: | |||||||||
Depreciation and amortization | (158) | (158) | - | NM | |||||
7,997 | 8,768 | (771) | (9%) | ||||||
Adjusted gross profit | $3,537 | $4,252 | |||||||
Adjusted gross margin | 30.7% | 32.7% |
About MCIMCI is a healthcare technology company focused on empowering patients and doctors with advanced technologies to increase access, improve quality, and reduce healthcare costs. As part of the healthcare community for over 30 years, MCI operates one of Canada’s leading primary care networks with approximately 280 physicians and specialists, serves more than one million patients annually and had nearly 300,000 telehealth visits last year, including online visits via mciconnect.ca. MCI additionally offers an expanding suite of occupational health service offerings that support a growing list of more than 650 corporate customers. Led by a proven management team of doctors and experienced executives, MCI remains focused on executing a strategy centered around acquiring technology and health services that complement the company’s current roadmap. For more information, visit mcionehealth.com.
For media enquiries please contact:Nolan Reeds | nolan@mcionehealth.com
Forward Looking StatementsCertain statements in this press release, constitute “forward-looking information” and "forward looking statements" (collectively, "forward looking statements") within the meaning of applicable Canadian securities laws and are based on assumptions, expectations, estimates and projections as of the date of this press release. Forward-looking statements include statements with respect to projected cash and liquidity, the Company’s need for financing, the anticipated completion of the Company’s additional debt financing, the Company’s ongoing review of strategic alternatives and the work of its Special Committee, the possibility of disposing of certain of the Company’s assets and plans for future cost reduction. The words “engaged in”, “evaluating”, “continuing to”, “potential”, “future”, “seeking”, “remains”, “implement”, “consider”, “possible”, “continually”, “ongoing”, “result in”, “able to”, “successful”, “progress”, “increasing”, “anticipates”, “begin”, “delivering” or variations of such words and phrases or statements that certain future conditions, actions, events or results “will”, “may”, “could”, “would”, “should”, “might” or “can”, or negative versions thereof, “occur”, “continue” or “be achieved”, and other similar expressions, identify forward-looking statements. Forward-looking statements are necessarily based upon management’s perceptions of historical trends, current conditions and expected future developments, as well as a number of specific factors and assumptions that, while considered reasonable by MCI as of the date of such statements, are outside of MCI's control and are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in the forward-looking statements ultimately being entirely or partially incorrect or untrue. Forward looking statements contained in this press release are based on various assumptions, including, but not limited to, the following: MCI's short- and medium-term liquidity and working capital needs, the availability of working capital and sources of short-term liquidity; the Company’s ability to continue to operate as a going concern; the Company’s ability to secure additional debt or equity financing and the terms on which that financing may be secured; MCI’s ability to close the transaction with a related party to gain access to the additional debt financing facility and the granting of approval of the debt facility by the Toronto Stock Exchange; MCI’s ability to find potential transaction partners to acquire the business or certain of its assets, the price which those transaction partners may be willing to pay and the timelines required to complete any potential transactions; MCI’s ability to achieve its growth and revenue strategies; the demand for MCI's products and fluctuations in future revenues; the availability of future business ventures, commercial arrangements and acquisition targets or opportunities and MCI’s ability to consummate them and to effectively integrate future acquisition targets into its platform; MCI’s ability to effectively roll out its smart referral system and monetize its data lake; MCI’s ability to grow its customer base in its corporate health services; the effects of competition in the industry; the requirement for increasingly innovative product solutions and service offerings; trends in customer growth; the stability of general economic and market conditions; currency exchange rates and interest rates; MCI's ability to comply with applicable laws and regulations; MCI's continued compliance with third party intellectual property rights; the anticipated effects of COVID-19; and that the risk factors noted below, collectively, do not have a material impact on MCI's business, operations, revenues and/or results. By their nature, forward-looking statements are subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct, and that objectives, strategic goals and priorities will not be achieved.
Readers are encouraged to review the “Liquidity and Capital Resources” section of the Company’s MD&A, together with Note 2(c) of the Company’s condensed interim consolidated financial statements, for the period ended March 31, 2023, which indicate the existence of material uncertainties that cast significant doubt on the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent on, among other things, its ability to meet its financing requirements on a continuing basis, to sell certain assets to generate short-term liquidity, to have access to financing and to generate positive operating results. The Company’s ability to satisfy its financing requirements and ultimately achieve necessary levels of profitability and positive cash flows from operations, to raise additional funds, to sell assets and to improve operating results are dependent on a number of factors outside the Company’s control and there can be no assurance that the Company will be able to do so in the future.
Known and unknown risk factors, many of which are beyond the control of MCI, could cause the actual results of MCI to differ materially from the results, performance, achievements or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled “Risk Factors” in MCI's annual information form dated March 31, 2023, which is available under MCI's SEDAR profile at www.sedar.com. The risk factors are not intended to represent a complete list of the factors that could affect MCI and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. MCI disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
1 Year MCI Onehealth Technologies Chart |
1 Month MCI Onehealth Technologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions